In one form or another, Medicare risk contracting with private health plans has been around for decades. The current iteration, Medicare Advantage, has become very popular and currently serves over a quarter of all beneficiaries. That popularity is endangered, however, by ideological hostility from the current administration and impending lower payment rates. Almost all beneficiaries live in the service area of at least one MA plan and 86% have access to a plan that includes Part D, or drug, coverage and no premium. MedPAC has been supportive of MA and of the concept of neutrality in spending on the same beneficiary whether in MA or the fee-for-service program. The Commission notes that Congress and CMS have continued to move in this direction. The Commission expressed approval of the quality improvement efforts of CMS, although it noted the misuse of a quality bonus plan authorized by Congress. Special needs plans are a category of MA plans with limited enrollment categories, like institutionalized or chronic disease patients. The authority for these plans expires in 2014 and the Commission recommends that this authority not be extended, except for a transition period for SNPs focusing on beneficiaries with a small number of serious, chronic conditions, and that institutionalized SNPs just become a permanent sub-category of MA plan and that SNPs covering dual eligibles also be treated as a permanent MA sub-category, so long as they take full clinical and financial responsibility for the beneficiary. In its status report on Part D, which is all private plans, the Commission notes good access, high satisfaction rates and generally under-control costs. The Commission also indicates the the competitive bidding design is likely leading to beneficiary switching of plans.
✅ Subscribe via Email
About this Blog
Healthy Skeptic Podcast
Research
MedPAC 2019 Report to Congress
June 18, 2019
Headlines
Tags
Access
ACO
Care Management
Chronic Disease
Comparative Effectiveness
Consumer Directed Health
Consumers
Devices
Disease Management
Drugs
EHRs
Elder Care
End-of-Life Care
FDA
Financings
Genomics
Government
Health Care Costs
Health Care Quality
Health Care Reform
Health Insurance
Health Insurance Exchange
HIT
HomeCare
Hospital
Hospital Readmissions
Legislation
M&A
Malpractice
Meaningful Use
Medicaid
Medical Care
Medicare
Medicare Advantage
Mobile
Pay For Performance
Pharmaceutical
Physicians
Providers
Regulation
Repealing Reform
Telehealth
Telemedicine
Wellness and Prevention
Workplace
Related Posts
Commentary
No Need for More CV-19 Vax Doses
February 5, 2025
No Need for More CV-19 Vax Doses
Studies continue to show essentially no benefit from additional doses of CV-19 vax.
Commentary
OK, Here We Go with New Job Numbers for the New Administration
February 4, 2025
OK, Here We Go with New Job Numbers for the New Administration
Nothing super dramatic in the first JOLTS release of 2025.
Commentary
Does Anyone Really Not Understand Trump at this Point?
February 4, 2025
Does Anyone Really Not Understand Trump at this Point?
What happened over three days in regard to tariffs was totally predictable if you understand…